Heron Therapeutics, INC /DE/

Heron Therapeutics has been notified by Nasdaq that its common stock failed to maintain the minimum $1.00 bid price requirement.

Heron Therapeutics held its 2026 Annual Meeting of Stockholders, with key proposals including director elections, auditor ratification, executive compensation, and equity plan amendments receiving stockholder approval.

Heron Therapeutics announced a U.S. District Court ruling invalidating key patents for its CINVANTI drug, with the company planning to appeal the decision.

Heron Therapeutics announced first quarter 2026 financial results, reporting $34.7 million in net revenue and reaffirming full-year guidance, driven by significant growth in its Acute Care franchise.

Heron Therapeutics has amended employment and retention agreements for its CEO and key executives to update severance, change-in-control, and restrictive covenant terms.

Heron Therapeutics announced strong Q4 and full-year 2025 financial results, driven by significant revenue growth in its Acute Care franchise and optimistic 2026 guidance.

Heron Therapeutics reported a net loss of $8.1 million for Q1 2026, with net product sales decreasing to $34.7 million compared to $38.9 million in the prior year period.

Heron Therapeutics reports strong acute care product sales growth and a significant debt refinancing, despite a one-time loss on debt extinguishment.

Heron Therapeutics reported a net income for the first half of 2025, driven by strong acute care product sales and reduced operating expenses, while successfully refinancing its debt.

Heron Therapeutics achieves profitability in Q1 2025, driven by strong growth in its acute care product portfolio and strategic cost management.

Heron Therapeutics saw a revenue increase in Q3 2024 compared to Q3 2023, while also reducing its net loss.

Heron Therapeutics saw a rise in product sales during the second quarter of 2024, but still experienced a net loss.

Heron Therapeutics reports increased net product sales driven by strong acute care performance, despite a net loss and ongoing patent litigation for its oncology products.

Heron Therapeutics details its financial performance for 2024, highlighting product sales growth and ongoing legal battles over key patents.

Heron Therapeutics' 2023 10-K filing highlights a year of commercial expansion, strategic partnerships, and cost-saving measures, alongside ongoing challenges in a competitive market.

Mark Earl Hensley, Chief Operating Officer of Heron Therapeutics, Inc. /De/, reported multiple transactions in common stock on July 31, 2026.

William P Forbes, EVP, Chief Development Officer of Heron Therapeutics, Inc. /De/, reported multiple transactions in common stock on July 30, 2026.

Ira Duarte, EVP, Chief Financial Officer of Heron Therapeutics, Inc. /De/, reported multiple transactions in common stock on July 30, 2026.

Craig A Collard, Chief Executive Officer and a Director of Heron Therapeutics, Inc. /De/, reported multiple transactions in common stock on July 30, 2026.

Craig A Collard, Chief Executive Officer and a Director of Heron Therapeutics, Inc. /De/, reported multiple transactions in common stock on July 19, 2026.

William P Forbes, EVP, Chief Development Officer of Heron Therapeutics, Inc. /De/, reported multiple transactions in common stock on July 19, 2026.

Heron Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 11, 2026, with key proposals including director elections and equity plan amendments.

Heron Therapeutics is seeking shareholder approval for the potential issuance of common stock exceeding 19.99% of current outstanding shares, stemming from the conversion of convertible senior unsecured promissory notes and Series A Convertible Preferred Stock.

Heron Therapeutics has scheduled its annual stockholder meeting for June 12, 2025, and is seeking votes on director elections, auditor ratification, executive compensation, and the frequency of executive compensation votes.

Heron Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 12, 2025, featuring proposals for director elections, auditor ratification, and executive compensation.

Heron Therapeutics is holding its 2024 Annual Meeting of Stockholders on June 13, 2024, to vote on several proposals, including the election of directors, ratification of the accounting firm, executive compensation, and amendments to the company's certificate of incorporation and equity incentive plans.

Rubric Capital Management LP and David Rosen increased their beneficial ownership in Heron Therapeutics, Inc. to 15.9% following the conversion of preferred stock and a convertible note issuance.

Heron Therapeutics has entered into a series of agreements, including a $66.38 million capital raise through common stock, preferred stock, and convertible notes, alongside a governance agreement granting a board seat to Rubric Capital Management LP.

Adage Capital Management, L.P., along with individuals Robert Atchinson and Phillip Gross, has filed a Schedule 13G amendment indicating zero beneficial ownership of Heron Therapeutics, Inc. common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Heron Therapeutics Inc. following an internal realignment.

Clearline Capital LP, Clearline Capital LLC, and Marc Majzner have jointly disclosed a 6.7% beneficial ownership stake in Heron Therapeutics, Inc.

The Vanguard Group reported a 5.35% beneficial ownership stake in Heron Therapeutics Inc. common stock as of December 31, 2025.

Clearline Capital LP, Clearline Capital LLC, and Marc Majzner have jointly disclosed a beneficial ownership of 5.3% in Heron Therapeutics, Inc. common stock.

The Vanguard Group has filed an amendment to its Schedule 13G, reporting a 4.61% beneficial ownership stake in Heron Therapeutics Inc.